CRISPR-Cas9 can be employed to correct the genetic mutation responsible for the enzyme deficiency in conditions such as hereditary tyrosinemia type 1, where a deficiency in fumarylacetoacetate hydrolase [FAH] leads to toxic metabolite accumulation [105]. This evidence concerns the gene FAH and Tyrosinemia type 1.